Obsidian Therapeutics Announces Closing of $115 Million Series B Financing

Funding to Advance Pipeline of Engineered TIL Therapies for Solid Tumors into Clinical Studies CAMBRIDGE, Mass., Sept. 9, 2021 -- (Healthcare Sales & Marketing Network) -- Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell ... Biopharmaceuticals, Venture Capital Obsidian Therapeutics, cytoDRiVE
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news